BioGenes offers the development of highly specific anti-idiotypic antibodies. Anti-idiotype antibodies are antibodies against the antigen binding site of another antibody.

The antigen binding site of the anti-idiotype antibody is similar in structure to the original antigen. Therefore, anti-idiotypic monoclonal antibodies can be used to mimic the structure of the original antigen. They can serve as surrogate for tumor-associated antigens in vaccination strategies by triggering humoral and cellular immune responses against the tumor antigen.

BioGenes’ scientists are specialized in complex projects and have developed premium quality anti-idiotypic antibodies even with small antibody amounts in less than four months.
Antibodies developed by BioGenes are a valuable basis for therapeutic antibody development and an appropriate tool for validating targets in proteomics research.

Please contact us for your special offer.